Compare OGN & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | ALMR |
|---|---|---|
| Founded | 1923 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 2026 |
| Metric | OGN | ALMR |
|---|---|---|
| Price | $13.51 | $24.22 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.40 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 382.4K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | $0.45 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $24.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $21.58 |
| 52 Week High | $13.60 | $29.43 |
| Indicator | OGN | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 49.80 |
| Support Level | $13.46 | N/A |
| Resistance Level | $13.60 | $29.06 |
| Average True Range (ATR) | 0.05 | 1.96 |
| MACD | -0.03 | -0.29 |
| Stochastic Oscillator | 35.71 | 0.17 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.